Click HERE to Register for the MS Beacon Newsletter
APRIL 9, 2020 - Written by BY JENNIFER POWELL
Zeposia’s recent approval in the U.S. is exciting news for all in the MS community. Unfortunately, we will need to table that excitement a bit longer. Despite its approval, the treatment’s commercial distribution will be delayed by the COVID-19 pandemic. I am confident, however, that it will be a game-changer once it’s readily available.
The Food and Drug Administration approved Zeposia (ozanimod) on March 25 to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis.Plus, Zeposia’s recent approval in the U.S. is exciting news for all in the MS community. Unfortunately, we will need to table that excitement a bit longer. Despite its approval, the treatment’s commercial distribution will be delayed by the COVID-19 pandemic. I am confident, however, that it will be a game-changer once it’s readily available.
The Food and Drug Administration approved Zeposia (ozanimod) on March 25 to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis.
Zeposia is an oral medication taken once daily. An oral alternative to injections and infusions is alluring. While not the first oral disease-modifying therapy (DMT), the trend looks promising. Most oral DMTs are easier to administer and safer to tolerate for multiple subtypes of MS. It is vital to learn how each DMT works and how that might affect your overall health.
I thought of changing my own DMT when Mayzent (sipinomod) was approved in March 2019. My twice-annual infusions of Rituxan had become arduous. That said, I have remained on Rituxan without incident since 2015.
Zeposia is an oral sphingosine-1 phosphate (S1P) receptor modulator developed by Celgene (a subsidiary of Bristol-Myers Squibb). It works by limiting the number of lymphocytes from exiting the lymph nodes. Much like we are sequestered in our homes, so too are the lymphocytes in theirs: the lymph nodes. Limiting their presence in the peripheral blood and spinal cord reduces inflammation. While similar to Gilenya (fingolimod) and Mayzent in efficacy for relapsing MS, Zeposia may be superior in terms of safety.
“Because [Zeposia] is somewhat more selective for the receptors with which it interacts, this would reduce some of the safety issues that have been seen with fingolimod,” said Jeffrey Cohen, MD, a neurologist with the Cleveland Clinic’s Mellen Center for MS, in an interview with Multiple Sclerosis News Today.
“The main side effects that we’re seeing are very minor nasal pharyngitis, headache, side effects such as that,” he added. “The receptor selectivity and also the titration regimen at the initiation of therapy largely avoids the cardiac side effects, which are the big worry with other S1P modulators, so we think that’s a big advantage.”
Advantage, indeed. Once our world gets its arms around this coronavirus, Celgene will start mass marketing and distribution of Zeposia. Although I am not planning on taking it, I am eager to see its impact on the MS community.
sourceThis article is posted and shared by: #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
0 Comments: